Immune-cell signaling and experimental aging
Lab research
Scope of investigation or explicitly identified community interest; not an established indication.1
Immune
Vilon
KE and immune-cell signaling
Investigational; this profile does not establish an approved use.
What does it do?
Length2 amino acids
Molecular weight · Da~275 Da
Pharmacokinetics
Class inferenceNot independently confirmed
Reference half-life5 min – 20 min12
Route / formulationSource page: Injectable. Exact PK route not verified.
The source identifies this as a class-level inference, not a measured half-life for this compound.
50%–84.1%of reference level
Illustrative scenario using an unverified reference estimate. Shading shows the reported half-life range. No midpoint is assumed.
About 3% remaining after 25 min–1.67 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Khavinson class-level dipeptide inference; Linkova et al. 2023 IJMS (PMID 37686182)
Source’s reported peak time: 1 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Scope of evidence
Clinical immune benefits and long-term safety of isolated Vilon were not established.1
Reported timelines
Reference & communitySource expectations
No acute felt effect days 1–10; laboratory immune endpoints weeks 2–4; longevity endpoints annual courses. No established human symptom timeline.13
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 10-20 mcg | Once daily for 10 days | Russian Label (IM)Reference report | 10 days per course | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source references sometimes concern thymalin/epithalamin rather than isolated Vilon/epitalon. Compatibility remains unverified. Source route wording IM or SubQ Source tabs Injectable | |||||
| IMIntramuscular | 10-20 mcg | Once daily for 10 days | Russian Label (IM)Reference report | 10 days per course | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source references sometimes concern thymalin/epithalamin rather than isolated Vilon/epitalon. Compatibility remains unverified. Source route wording IM or SubQ Source tabs Injectable | |||||
| SubQSubcutaneous | 10-20 mcg per injection | Once daily for 10 days, repeated annually or bi-annually | Geroprotective (Annual Cycle)Reference report | 10 days per course | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source references sometimes concern thymalin/epithalamin rather than isolated Vilon/epitalon. Compatibility remains unverified. Source route wording IM or SubQ Source tabs Injectable | |||||
| IMIntramuscular | 10-20 mcg per injection | Once daily for 10 days, repeated annually or bi-annually | Geroprotective (Annual Cycle)Reference report | 10 days per course | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source references sometimes concern thymalin/epithalamin rather than isolated Vilon/epitalon. Compatibility remains unverified. Source route wording IM or SubQ Source tabs Injectable | |||||
| Oral | 200 mcg (2 capsules at 100 mcg each) | Once daily for 30 days | Russian Label (Oral)Reference report | 30 days (Russian BAFS label) | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source references sometimes concern thymalin/epithalamin rather than isolated Vilon/epitalon. Compatibility remains unverified. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 10 days per course
- Break
- Annual or bi-annual cycles per Khavinson geroprotective protocol framework
Reported timing
No published Cmax or Tmax data for Vilon. As a dipeptide, plasma half-life is estimated in the range of minutes to less than one hour, consistent with short-peptide class behavior.
Oral
- Use period
- 30 days (Russian BAFS label)
- Break
- Per product label; Khavinson framework references quarterly cycles
Reported timing
No published Tmax or bioavailability data for oral Vilon. Oral route is mechanistically plausible for a dipeptide but not confirmed in human PK studies.
Side effects & safety
Mixture attribution
Thymalin extract studies cannot establish efficacy or safety of isolated Vilon.
1Laboratory scope
THP-1 signaling results do not reveal clinical infection outcomes or long-term immune effects.
1Unknown safety
Safety inference from thymalin does not validate isolated Vilon or oral products.
Caution
Transplant immunosuppression, active autoimmune disease, allergy and pregnancy/lactation.
Stop symptoms
Allergy, autoimmune flare, persistent local reactions or systemic symptoms.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Immunosuppressants
Avoidance reportedPotential opposition to treatment.13
Reference report · Pep-Pedia label: Avoid CombinationCorticosteroids
Caution reportedImmune interaction uncertain.13
Reference report · Pep-Pedia label: Use CautionThymalin
Unverified pairingContains KE; duplication, not proven synergy.13
Reference report · Pep-Pedia label: SynergisticThymosin Alpha-1
Unverified pairingNo human combination study.13
Reference report · Pep-Pedia label: SynergisticEpitalon
Unverified pairingParent-extract protocols not proof.13
Reference report · Pep-Pedia label: CompatibleThymulin
Related compoundOverlapping immune endpoints.13
Reference report · Pep-Pedia label: SimilarLivagen
Unverified pairingCell-culture pairing, not safety proof.13
Reference report · Pep-Pedia label: CompatibleOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.3
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes a 10 mg dry vial with saline and same-day use.
- Solvents mentioned
- 0.9% sterile sodium chloride
- Reported parameters
- Reported example: 1–2 mL of 0.9% sodium chloride. · Dry material: reported 2–8°C. · The source says not to store prepared solution.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
The source describes supplement capsules, with no specified meal-timing restriction.
- Form
- Source describes a prepared product
- Reported parameters
- Reported storage: room temperature according to the product label.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite lyophilized powderReported appearanceClear reconstituted solutionReported appearanceSealed vial with batch number and expiryReported appearanceRefrigerated cold chainReported variationVerify product is Vilon (KE), not Vesugen (KED)Reported variationResearch-chemical supply chain for Western marketsReported concernCloudy, yellow, or particulate solution after reconstitution
13Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
13Lyophilized: 2-8 degrees C. Reconstituted: use same day.
Room temperature per Russian BAFS product label
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Clinical immune benefits and long-term safety of isolated Vilon were not established.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
PreclinicalSource context
Source references sometimes concern thymalin/epithalamin rather than isolated Vilon/epitalon. Compatibility remains unverified.
Compound identity & other names
Vilon is the Lys–Glu dipeptide, studied in cellular signaling and experimental aging models. Findings for thymalin extract or other peptides in a study panel do not demonstrate an effect of isolated Vilon in patients.
Other names: KE
Investigational; this profile does not establish an approved use.
Pep-Pedia identity record
2 amino acids (dipeptide) · ~275 Da
H-Lys-Glu-OHReference description; checked chemical identity takes precedence when available.13
How it may work
Proposed DNA-motif interaction modulates cytokine transcription and lymphocyte-related endpoints.13
Immune-cell signaling experiment
The experiment included Vilon in a peptide panel tested on THP-1 cells. Pathway readouts do not demonstrate prevention of infection or longer human life.
1Research areas and evidence gaps
Immune-cell signaling and experimental aging. Scope of investigation or explicitly identified community interest; not an established indication.1
- Clinical immune benefits and long-term safety of isolated Vilon were not established.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Additional uses listed by Pep-Pedia
Immune. T-cell maturation and cytokine modulation.13
Aging. Ex-vivo chromatin effects and geroprotection claims from older protocols.13
Inflammation. Cell-culture TNF-alpha reduction; oral clinical effectiveness uncertain.13
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.3
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
The targeted newer-literature check did not identify an additional verified exact-compound clinical outcome study beyond the retained evidence. This is not a systematic-review conclusion.
- Checked
- 2026-10-12
- Search
- Vilon peptide study 2025 2026
- Catalog
- Pep-Pedia ↗ · 10 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll Results availability
The source explicitly reported no responses when checked.
References
Original sources and review status. Open a reference to read its summary.
1Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell LineAbstract checked
AI-PREPARED SUMMARY
Vilon and other peptides were tested for signaling effects in a monocytic cell line.
Immune-cell signaling experiment
The experiment included Vilon in a peptide panel tested on THP-1 cells. Pathway readouts do not demonstrate prevention of infection or longer human life.
Pep-Pedia bibliography · Checked 2026-10-12
2Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell LineAbstract checked
AI-PREPARED SUMMARY
Vilon and other peptides were tested for signaling effects in a monocytic cell line.
Pep-Pedia bibliography · Checked 2026-10-12
3Pep-Pedia: VilonCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
4Linkova N, Khavinson V, Diatlova A, et al. (2023). The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences, 24(17), 13377.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: KE reduced TNF-alpha in stimulated cells more than the Thymalin complex; the comparison does not establish a clinical COVID treatment.
Reported population / model
Human PBMCs
Reported study details
LPS-stimulated · KE + EW individual and combined · Molecular docking + in vitro
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Lezhava T, Jokhadze T (2023). Epigenetic modification of old chromatin by peptide bioregulators. Georgian Medical News, (338), 132-137.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Several peptide bioregulators changed elderly-donor lymphocyte chromatin; no patient functional or lifespan outcome was tested.
Reported population / model
Human
Reported study details
Ex vivo lymphocytes · Elderly donors aged 75-88 · KE, Epitalon, Cortagen, Livagen
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Khavinson VKh, Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters, 24(3-4), 233-240.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The mortality observations concern Thymalin and Epithalamin extracts rather than isolated Vilon; unblinded observational findings cannot establish lifespan extension.
Reported population / model
Human
Reported study details
n=266 elderly · 6-8 year follow-up · Open-label observational
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Khavinson VK, Linkova NS, Kvetnoy IM, et al. (2020). Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of Experimental Biology and Medicine, 170(1), 118-122.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The experiment used the Thymalin mixture, not isolated KE; changes in cultured stem-cell markers cannot identify Vilon's individual effect.
Reported population / model
Human HSCs
Reported study details
In vitro · CD117, CD28, CD44 markers
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM (2021). The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews, 11(4), 377-382.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
9Linkova N, Khavinson V, Diatlova A, et al. (2023). The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences, 24(17), 13377.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Khavinson VK, Linkova NS, Kvetnoy IM, et al. (2020). Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of Experimental Biology and Medicine, 170(1), 118-122.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM (2021). The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews, 11(4), 377-382.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Pep-Pedia: Vilon — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 5 min – 20 min and a peak time of 1 min. Stated attribution: Khavinson class-level dipeptide inference; Linkova et al. 2023 IJMS (PMID 37686182). The source identifies this as a class-level inference, not a measured half-life for this compound. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
13Pep-Pedia: Vilon — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12